Staphylococcus aureus is one of the main causes of bacterial infection worldwide, notably responsible for hospital-acquired ...

A new study published in the Proceedings of the National Academy of Sciences has offered insight into how Staphylococcus ...

An international research group led by the Helmholtz Center for Infection Research (HZI) has discovered a promising new drug candidate against severe lung infections caused by the hospital germ ...

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company ...

Armata Pharmaceuticals is a Hold until Phase 3 AP-SA02 data, given a funding-dependent profile and limited margin for error.

As the threat of antibiotic resistance grows, a Swansea University academic has led the development of a novel technology capable of killing some of the most dangerous bacteria known to medicine—with ...

Detailed price information for Armata Pharmaceuticals Inc (ARMP-A) from The Globe and Mail including charting and trades.

Researchers have discovered that Staphylococcus aureus can rapidly evolve within a single person's microbiome. They found that in people with eczema, S. aureus tends to evolve to a variant with a ...

Pneumonia caused by the bacterium Staphylococcus aureus is one of the most dangerous infections that can occur in hospital. Particularly worrying are multi-resistant strains, against which many ...